Fosamax Metabolism and Energy Expenditure: What the Evidence Actually Shows

How Alendronate Is Absorbed: Strict Fasting Is Not Optional

Oral bioavailability of alendronate is low. Under properly fasting conditions, only about 0.6% to 0.7% of the ingested dose reaches systemic circulation, and food or beverages consumed within 30 minutes of dosing can reduce that fraction by as much as 60% [1]. The FDA-approved labeling specifies that patients must swallow the tablet with 6 to 8 ounces of plain water at least 30 minutes before the first food, beverage, or medication of the day [2].

Why Food Abolishes Absorption

Calcium and other divalent cations in food bind alendronate in the gastrointestinal lumen, forming insoluble complexes that cannot cross the intestinal epithelium. Even coffee or orange juice, consumed simultaneously, can drop mean peak plasma concentration (Cmax) by roughly 60% relative to the fasted state [1]. This interaction is not pharmacodynamic; it is purely physicochemical chelation in the gut.

Esophageal Transit Requirements

Because alendronate is a potent inhibitor of osteoclast farnesyl pyrophosphate synthase, any residual drug contacting the esophageal mucosa can cause erosive esophagitis. Patients must remain upright for at least 30 minutes post-dose. Enteric coating does not fully mitigate mucosal risk, so proper dosing posture remains a clinical priority [2].

Alendronate Pharmacokinetics: Distribution, Non-Metabolism, and Elimination

Plasma Protein Binding and Rapid Skeletal Uptake

After reaching systemic circulation, alendronate binds albumin at approximately 78%. The drug is then taken up rapidly by bone surfaces with high affinity for hydroxyapatite. Within hours of dosing, roughly 50% of the absorbed fraction is deposited on bone mineral; the remaining fraction is excreted renally without structural modification [1].

Zero Hepatic Metabolism

Alendronate is not a substrate for cytochrome P450 enzymes. No phase I or phase II metabolites have been detected in human plasma, urine, or feces [1]. This is clinically significant for two reasons. First, drug-drug interactions mediated through CYP3A4 or CYP2D6 are not a concern. Second, hepatic impairment does not alter dosing. Patients with cirrhosis or elevated transaminases require no alendronate dose adjustment based on pharmacokinetic grounds alone.

Renal Clearance and the "Bone Bank" Concept

Renally cleared alendronate exits the body within 24 to 72 hours of dosing. The fraction that incorporates into bone matrix is effectively sequestered. As osteoclasts resorb old bone over years to decades, small amounts of drug are released back into the circulation and re-excreted renally. The estimated terminal skeletal half-life exceeds 10 years, which explains why a single course of therapy can suppress bone turnover markers for months to years after the drug is discontinued [1][3].

Renal dosing adjustment is necessary for patients with creatinine clearance <35 mL/min; the drug is not recommended in that population due to the risk of renal accumulation [2].

Does Alendronate Affect Energy Expenditure or Thermogenesis?

This is the question with the least straightforward answer in the alendronate literature. The short version: no randomized controlled trial in humans has demonstrated that alendronate directly raises or lowers resting energy expenditure (REE) or thermogenesis. Several indirect mechanisms, however, deserve careful examination.

Bone as an Endocrine Organ: The Osteocalcin Hypothesis

Research from Gerard Karsenty's laboratory at Columbia University established that osteocalcin, a protein secreted by osteoblasts, acts as a hormone capable of stimulating insulin secretion, improving insulin sensitivity, and increasing energy expenditure in mice. In a landmark 2007 Cell paper, Ferron et al. Showed that osteocalcin-deficient mice developed obesity and glucose intolerance [4]. Subsequent work demonstrated that uncarboxylated osteocalcin promotes thermogenesis in adipocytes and skeletal muscle.

Alendronate suppresses bone turnover. Because osteocalcin is synthesized and released during the remodeling cycle, long-term bisphosphonate therapy reduces circulating osteocalcin concentrations. A 12-month study in postmenopausal women receiving alendronate 70 mg weekly reported a mean 25% decline in serum osteocalcin compared to baseline [5]. Whether this reduction in osteocalcin translates to measurable changes in human energy expenditure remains unresolved.

What Human Studies Do and Do Not Show

The direct evidence in humans is sparse. A cross-sectional analysis published in the Journal of Bone and Mineral Research did not find significant differences in REE between bisphosphonate users and non-users after adjusting for lean mass and age [3]. Lean mass is the dominant determinant of REE, accounting for approximately 60% to 70% of variance in resting calorie burn. Alendronate does not change lean mass meaningfully over 1 to 3 years of treatment.

One prospective sub-study within the Fracture Intervention Trial (FIT) examined body composition via DXA at baseline and 36 months. Alendronate did not significantly alter fat mass or lean mass compared to placebo [3][6]. Without a lean mass change, a biologically plausible mechanism for REE alteration is absent.

Brown Adipose Tissue and Bisphosphonates: Preclinical Signal

Bisphosphonates can deplete tissue macrophages, and brown adipose tissue (BAT) contains macrophages that contribute to thermogenic activation via IL-4 signaling. In murine models, clodronate liposome-mediated macrophage depletion reduced cold-induced thermogenesis. Alendronate's macrophage effects in BAT have not been formally studied in humans, and extrapolating rodent BAT biology to adult human patients is premature [7].

Clinical Decision Framework: When to Consider Metabolic Monitoring in Alendronate Users

Clinicians may consider tracking fasting glucose, HbA1c, and body weight annually in postmenopausal patients on long-term alendronate (more than 5 years) who also have prediabetes or metabolic syndrome, not because the drug is known to worsen metabolic parameters, but because the suppression of osteocalcin-related bone-muscle crosstalk remains a biologically plausible concern that current trials have not fully excluded. This monitoring adds no drug-specific risk and may detect incident dysglycemia early.

The FIT Trial: Primary Evidence for Alendronate's Clinical Benefit

The Fracture Intervention Trial (FIT) remains the cornerstone efficacy dataset for alendronate. Published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55 to 81 with low bone mineral density (femoral neck T-score of -1.6 or lower) and randomized them to alendronate 5 mg daily (later increased to 10 mg) versus placebo over 36 months [6].

Key results from FIT:

• Vertebral fractures: 47% relative risk reduction in radiographic vertebral fractures (8.0% placebo vs. 4.3% alendronate; P<0.001) [6]
• Hip fractures: 51% relative risk reduction (2.2% placebo vs. 1.1% alendronate; P = 0.047) [6]
• Wrist fractures: 48% relative risk reduction [6]

The trial did not measure resting energy expenditure, thermogenesis, or serum osteocalcin as pre-specified outcomes, which is why FIT cannot answer the metabolic question directly.

Bone Mineral Density Gains and Body Composition

In FIT, lumbar spine BMD increased a mean of 6.2% from baseline in the alendronate group versus 1.0% in the placebo group at 36 months [6]. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines cite these data as the basis for alendronate remaining a first-line agent for postmenopausal osteoporosis with a FRAX 10-year hip fracture probability of 3% or higher [8].

"Alendronate has one of the most extensive safety and efficacy databases of any osteoporosis therapy, with consistent vertebral and nonvertebral fracture risk reduction across multiple large trials," states the AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 [8].

Alendronate and Glucose Metabolism: Emerging Data

Observational Evidence

Several large observational studies have examined whether bisphosphonate use associates with diabetes incidence. A 2016 analysis using the Taiwan National Health Insurance Database (N = 8,494 bisphosphonate users vs. 8,494 matched controls) found a 33% lower hazard of new-onset type 2 diabetes in bisphosphonate users over a mean follow-up of 3.7 years [9]. The mechanism proposed was osteocalcin-mediated, though confounding by indication (patients on bisphosphonates may have healthier baseline metabolic profiles) limits causal inference.

A separate case-control analysis in Diabetes Care found that current bisphosphonate users had roughly 23% lower odds of insulin resistance markers compared to osteoporosis patients not receiving treatment, after adjustment for age, BMI, and corticosteroid use [9].

Why Causality Cannot Be Confirmed Yet

Observational data carry inherent limitations. Patients prescribed alendronate are typically under closer medical supervision, more likely to exercise for bone health, and may have lower baseline fracture-related immobility, all of which independently reduce diabetes risk. No randomized trial has been powered to detect a diabetes prevention signal for alendronate, and no such trial is currently registered on ClinicalTrials.gov as of early 2025.

Drug Interactions Relevant to Metabolic Co-Management

NSAIDs and GI Risk

Concurrent use of alendronate with nonsteroidal anti-inflammatory drugs approximately doubles the risk of upper GI adverse events compared to either drug alone [2]. In patients managed for metabolic bone disease alongside inflammatory conditions, timing alendronate and NSAIDs on separate days or switching to IV zoledronic acid may reduce GI burden.

Calcium and Vitamin D Co-Administration

Adequate calcium and vitamin D are prerequisites for alendronate to work properly. Hypocalcemia before treatment blunts the BMD response and risks symptomatic hypocalcemia after dosing. The Endocrine Society 2019 clinical practice guideline recommends ensuring serum 25-hydroxyvitamin D is at least 20 ng/mL before initiating any bisphosphonate [10].

Proton Pump Inhibitors

PPIs reduce gastric acid and theoretically may reduce esophageal mucosal injury risk. They do not, however, improve alendronate absorption. The FDA label does not require PPI co-prescription, though some clinicians prescribe it empirically in patients with a history of GERD [2].

Long-Term Use: Drug Holidays and Residual Pharmacodynamic Effect

When to Stop and Why

The American Society for Bone and Mineral Research (ASBMR) task force recommends considering a drug holiday after 5 years of oral alendronate in patients whose hip T-score remains above -2.5 and who have no prior hip or vertebral fracture [3]. The rationale is the multi-year skeletal retention described above: alendronate continues to suppress bone turnover for up to 5 years after discontinuation because the drug slowly leaches from bone back into the remodeling space.

Atypical Femoral Fractures

Long-term alendronate use (generally beyond 5 years) has been associated with atypical femoral fractures (AFFs), stress fractures of the subtrochanteric or diaphyseal femur. The absolute risk is approximately 3.2 to 50 per 100,000 person-years, which is substantially lower than the vertebral fracture risk that alendronate prevents [3]. Patients who develop thigh or groin pain on long-term therapy should have bilateral femoral radiographs.

"The task force concludes that the benefits of bisphosphonate treatment clearly outweigh the risks in women with a high fracture risk, but that patients at lower risk may benefit from a drug holiday after 3 to 5 years of treatment," stated the 2016 ASBMR Task Force Report on Atypical Femoral Fractures [3].

Dosing Reference for Clinicians

| Indication | Dose | Frequency | |---|---|---| | Postmenopausal osteoporosis (treatment) | 70 mg | Once weekly | | Postmenopausal osteoporosis (prevention) | 35 mg | Once weekly | | Male osteoporosis | 70 mg | Once weekly | | Glucocorticoid-induced osteoporosis | 5 mg daily (10 mg if postmenopausal without estrogen) | Daily | | Paget disease of bone | 40 mg | Daily for 6 months |

All oral doses require 30-minute pre-meal fasting, upright posture for 30 minutes post-dose, and plain water only during the fasting window [2].

Monitoring Parameters During Alendronate Therapy

Clinicians should assess the following at baseline and periodically during treatment:

• Serum creatinine and creatinine clearance before initiation and annually in older adults
• Serum calcium and 25-hydroxyvitamin D at baseline; correct deficiency before starting
• Bone turnover markers, specifically serum CTX (C-terminal telopeptide), can be measured at 3 to 6 months to confirm adherence and response; a 50% or greater reduction from baseline indicates adequate suppression [10]
• DXA scan of lumbar spine and hip at baseline and every 1 to 2 years during active treatment
• Dental evaluation before starting therapy in patients requiring major dental procedures, given the low but real risk of medication-related osteonecrosis of the jaw (MRONJ)

In patients with co-existing metabolic syndrome or prediabetes, annual fasting glucose and HbA1c monitoring is reasonable given the theoretical osteocalcin-glucose connection, though this is not currently a standard guideline recommendation.